Jinxin Fertility Group Debuts in US$390 Million Hong Kong IPO

June 25, 2019

Hong Kong – Paul Hastings, a leading global law firm, announced today that it has advised Morgan Stanley Asia Limited and CLSA Capital Markets Limited as joint sponsors in the US$390 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange of Chinese healthcare company Jinxin Fertility Group Limited (“Jinxin Fertility”).

Jinxin Fertility is the first assisted reproductive services (“ARS”) company listed on the Hong Kong Stock Exchange and a leading ARS provider in China and the United States. Paul Hastings has acted in some of the most significant biotech and healthcare company listings in Hong Kong including Ascletis Pharma, the first listing under Chapter 18A and CanSinoBIO, the first vaccine company listed on the Hong Kong Stock Exchange.

The Paul Hastings team was led by Raymond Li, global partner and Chair of Greater China practice, and corporate partner Zhaoyu Ren with support from Washington, D.C. partner Charles Patrizia, Hong Kong associates Isabelle Wu, Yang Kang Chan, Joyce Fung, Century City associate Vivian Tsai, China associate Berton Wang and China advisor Janet Yuan.

At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.